Agilent Technologies Inc, USA, has announced plans to introduce its DNA micro array-based genomics solutions into Indias growing life sciences market. Agilent currently sells technologies for the chemical, environmental and pharmaceutical manufacturing markets in India, and is a biotech leader. The company expects to expand its presence into industries such as medical research, drug discovery and agro-biotech.
"Agilents Life Sciences and Chemical Analysis (LSCA) business witnessed double-digit growth in India last year, driven by the countrys booming biotechnology, agriculture, information technology and pharmaceuticals industries. India is now LSCAs fourth-largest country of business in Asia, and one of the fastest growing zones. We expect this growth to continue as we launch our industry- leading solutions for the life sciences sector into areas such as genomics and proteomics research," informed Sanjeev Dhar, Country Manager for the LSCA Business in India.
Agilents initial plans focus on introducing its DNA microarray-based genomics solutions, which improve the productivity of gene-expression and genomics research. Also known as DNA chips or biochips, microarrays are small pieces of glass dotted with thousands of strands of DNA, each of which corresponds to a specific gene in the genome. In a single experiment, microarrays can measure genome-wide differences between diseased and healthy cells.
Agilent Technologies is a leading supplier of life science research systems that enable scientists to understand complex biological processes, determine disease mechanisms and accelerate drug discovery. Engineered for sensitivity, reproducibility and workflow productivity, Agilents integrated biology solutions include instrumentation, micro fluidics, software, microarrays, consumables and services for genomics, proteomics and metabolomics applications.